BRPI0821395A2 - Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático - Google Patents

Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático

Info

Publication number
BRPI0821395A2
BRPI0821395A2 BRPI0821395-0A BRPI0821395A BRPI0821395A2 BR PI0821395 A2 BRPI0821395 A2 BR PI0821395A2 BR PI0821395 A BRPI0821395 A BR PI0821395A BR PI0821395 A2 BRPI0821395 A2 BR PI0821395A2
Authority
BR
Brazil
Prior art keywords
gemcitabine
triglycerides
salts
combination
fatty acids
Prior art date
Application number
BRPI0821395-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penney
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of BRPI0821395A2 publication Critical patent/BRPI0821395A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0821395-0A 2007-12-19 2008-12-18 Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático BRPI0821395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
BRPI0821395A2 true BRPI0821395A2 (pt) 2015-06-16

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821395-0A BRPI0821395A2 (pt) 2007-12-19 2008-12-18 Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático

Country Status (15)

Country Link
US (1) US8946190B2 (OSRAM)
EP (1) EP2231166B1 (OSRAM)
JP (1) JP5473937B2 (OSRAM)
KR (1) KR101603351B1 (OSRAM)
CN (1) CN101903028B (OSRAM)
AU (1) AU2008338204B2 (OSRAM)
BR (1) BRPI0821395A2 (OSRAM)
CA (1) CA2708679C (OSRAM)
DK (1) DK2231166T3 (OSRAM)
ES (1) ES2414617T3 (OSRAM)
MX (1) MX2010006867A (OSRAM)
NZ (1) NZ586249A (OSRAM)
PT (1) PT2231166E (OSRAM)
TW (1) TWI448290B (OSRAM)
WO (1) WO2009076761A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
SG10201807622WA (en) * 2010-10-27 2018-10-30 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP3578170A1 (en) * 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641356B2 (en) * 1989-03-13 1993-09-23 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
WO2002083120A2 (en) 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
AP2005003367A0 (en) * 2003-02-07 2005-09-30 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis.
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
AU2008338204B2 (en) 2015-03-05
PT2231166E (pt) 2013-06-17
ES2414617T3 (es) 2013-07-22
TWI448290B (zh) 2014-08-11
DK2231166T3 (da) 2013-06-24
CA2708679A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
CA2708679C (en) 2016-11-15
CN101903028A (zh) 2010-12-01
WO2009076761A1 (en) 2009-06-25
TW200934494A (en) 2009-08-16
US8946190B2 (en) 2015-02-03
CN101903028B (zh) 2013-06-05
MX2010006867A (es) 2010-08-31
US20100273731A1 (en) 2010-10-28
JP2011506492A (ja) 2011-03-03
JP5473937B2 (ja) 2014-04-16
KR101603351B1 (ko) 2016-03-14
EP2231166B1 (en) 2013-03-20
KR20100101134A (ko) 2010-09-16
AU2008338204A1 (en) 2009-06-25
NZ586249A (en) 2012-05-25
HK1151244A1 (en) 2012-01-27
EP2231166A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
BRPI0821395A2 (pt) Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático
BRPI0818963A2 (pt) Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0906327A2 (pt) Folha de registro e método para fabricar folha de registro.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0817396A2 (pt) Método para tratar deficiência de vitamina b12 num indivíduo e composição farmacêutica para tratar deficiência de vitamina b12 num individuo
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0908260A2 (pt) Dispositivo para tratamento térmico
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PT2178796T (pt) Método contínuo para tratamento de líquidos e fabrico de certos constituintes
BRPI0920166A2 (pt) conjuntos para reparo de alimentos e métodos relacionados
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0812233A2 (pt) Métodos e dispositivo para substituição exata de dna alvo em organismos eucarióticos.
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0720604B8 (pt) composição e método para detecção de desmineralização
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI1006130A2 (pt) método e aparelho para fabricação de artigos absorventes com junções laterais.
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
PT2049097T (pt) Composição e método para ligar acetaldeído no estômago
BRPI0716653A2 (pt) permutador de calor plÁstico e mÉtodo para fabricar o mesmo
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI0913136A2 (pt) método para produzir uma peça e peça.
BRPI0811160A2 (pt) Aquecedor e método de operação

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PROMETIC PHARMA SMT LIMITED (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.